Home › Companies › CG Oncology, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and CG Oncology, Inc.’s Form 8-K, filed June 8, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 4, 2026: 4 items on CG Oncology, Inc.’s Form 8-K, filed June 8, 2026: 2 elected · 2 approved.
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2024-2025 2025-2026
Explore CG Oncology, Inc. in the interactive database Compare manager voting policies
These tallies are CG Oncology, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 8, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Christina Rossi | 67,531,501 | -- | -- | 89,825 | 16,216,685 | 99.9% | Elected | — |
| Elect Director: Victor Tong, Jr. | 62,401,874 | -- | -- | 5,219,452 | 16,216,685 | 92% | Elected | — |
| 2. Ratification of the Selection of Independent Registered Public Accounting Firm | 83,711,522 | 4,103 | 122,386 | -- | -- | 99.9% | Approved | — |
| 3. Advisory Vote on Executive Compensation | 65,894,959 | 1,603,011 | 123,356 | -- | 16,216,685 | 98% | Approved | — |
Source: CG Oncology, Inc., Form 8-K, filed with the SEC on June 8, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
259 asset managers disclosed a vote on at least one CG Oncology, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of CG Oncology, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: To elect the Board's two nominees for Class II director named as nominees to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Christina Rossi
CG Oncology, Inc.’s own tally for this item (“Elect Director: Christina Rossi”): 67,531,501 for, 89,825 withheld, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the two persons listed below as Class II directors, each to serve until the Company's 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified, or until their earlier death, resignation or rem…”
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 86 asset managers below reported 28,865,680 for, 22,684 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,215,536 | 0 | 0 | 0 | For |
| T. Rowe Price | 6,951,557 | 0 | 0 | 0 | For |
| Fidelity | 2,911,157 | 0 | 0 | 0 | For |
| BlackRock | 1,829,138 | 0 | 0 | 0 | For |
| Jackson National | 785,996 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 727,381 | 0 | 0 | 0 | For |
| Charles Schwab | 541,958 | 0 | 0 | 0 | For |
| State Street | 405,333 | 0 | 0 | 0 | For |
| AllianceBernstein | 388,943 | 0 | 0 | 0 | For |
| Legg Mason | 381,329 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 366,397 | 0 | 0 | 0 | For |
| First Trust | 330,663 | 0 | 0 | 0 | For |
| Prudential/PGIM | 282,523 | 0 | 0 | 0 | For |
| Equitable | 251,573 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 245,891 | 0 | 0 | 0 | For |
| Lord Abbett | 227,058 | 0 | 0 | 0 | For |
| Putnam | 222,650 | 0 | 0 | 0 | For |
| Hartford | 205,514 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 191,487 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 176,920 | 0 | 0 | 0 | For |
| Goldman Sachs | 161,696 | 0 | 0 | 0 | For |
| John Hancock | 138,297 | 0 | 0 | 0 | For |
| MFS | 136,863 | 0 | 0 | 0 | For |
| Federated Hermes | 121,134 | 0 | 0 | 0 | For |
| TIAA | 120,636 | 0 | 0 | 0 | For |
Showing the 25 largest of 86 asset managers. All 86 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: To elect the Board's two nominees for Class II director named as nominees to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Victor Tong, Jr.
CG Oncology, Inc.’s own tally for this item (“Elect Director: Victor Tong, Jr.”): 62,401,874 for, 5,219,452 withheld, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the two persons listed below as Class II directors, each to serve until the Company's 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified, or until their earlier death, resignation or rem…”
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 86 asset managers below reported 27,685,863 for, 1,202,491 withheld, 10 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,212,889 | 0 | 10 | 2,637 | For |
| T. Rowe Price | 6,951,557 | 0 | 0 | 0 | For |
| Fidelity | 2,911,157 | 0 | 0 | 0 | For |
| BlackRock | 1,829,138 | 0 | 0 | 0 | For |
| Jackson National | 737,524 | 0 | 0 | 48,472 | Mixed |
| FRANKLIN STRATEGIC SERIES | 727,381 | 0 | 0 | 0 | For |
| Charles Schwab | 541,958 | 0 | 0 | 0 | For |
| State Street | 404,854 | 0 | 0 | 479 | For |
| AllianceBernstein | 388,943 | 0 | 0 | 0 | For |
| Legg Mason | 381,329 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 366,397 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 0 | 330,663 | Withhold |
| Prudential/PGIM | 232,939 | 0 | 0 | 49,584 | Mixed |
| Equitable | 251,573 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 245,891 | 0 | 0 | 0 | For |
| Lord Abbett | 227,058 | 0 | 0 | 0 | For |
| Putnam | 222,650 | 0 | 0 | 0 | For |
| Hartford | 205,514 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 191,487 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 176,920 | Withhold |
| Goldman Sachs | 161,696 | 0 | 0 | 0 | For |
| John Hancock | 122,526 | 0 | 0 | 15,771 | Mixed |
| MFS | 0 | 0 | 0 | 136,863 | Withhold |
| Federated Hermes | 121,134 | 0 | 0 | 0 | For |
| TIAA | 120,636 | 0 | 0 | 0 | For |
Showing the 25 largest of 86 asset managers. All 86 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's Named Executive Officers.
CG Oncology, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 65,894,959 for, 1,603,011 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,215,533 | 3 | 0 | 0 | For |
| T. Rowe Price | 6,951,557 | 0 | 0 | 0 | For |
| Fidelity | 2,911,157 | 0 | 0 | 0 | For |
| BlackRock | 1,829,138 | 0 | 0 | 0 | For |
| Jackson National | 785,996 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 727,381 | 0 | 0 | 0 | For |
| Charles Schwab | 541,958 | 0 | 0 | 0 | For |
| State Street | 405,184 | 149 | 0 | 0 | For |
| AllianceBernstein | 388,943 | 0 | 0 | 0 | For |
| Legg Mason | 381,329 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 366,397 | 0 | 0 | 0 | For |
| First Trust | 330,663 | 0 | 0 | 0 | For |
| Prudential/PGIM | 282,523 | 0 | 0 | 0 | For |
| Equitable | 251,573 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 245,891 | 0 | 0 | 0 | For |
| Lord Abbett | 227,058 | 0 | 0 | 0 | For |
| Putnam | 222,650 | 0 | 0 | 0 | For |
| Hartford | 205,514 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 191,487 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 176,920 | 0 | 0 | 0 | For |
| Goldman Sachs | 161,696 | 0 | 0 | 0 | For |
| John Hancock | 138,297 | 0 | 0 | 0 | For |
| MFS | 136,863 | 0 | 0 | 0 | For |
| Federated Hermes | 121,134 | 0 | 0 | 0 | For |
| TIAA | 120,636 | 0 | 0 | 0 | For |
Fund voting reports, all 84 managers: 28,834,800 for, 30,727 against, 22,684 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 10,067,733 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 7,010,964 | 0 | 0 | 0 | For |
| Decheng Capital LLC | 6,371,669 | 0 | 0 | 0 | For |
| Wellington | 4,025,019 | 0 | 0 | 0 | For |
| Foresite Capital Management VI LLC | 2,221,474 | 0 | 0 | 0 | For |
| Fidelity | 1,985,979 | 126 | 0 | 0 | For |
| BlackRock | 1,410,709 | 7,798 | 0 | 0 | For |
| State Street | 1,312,215 | 873 | 0 | 0 | For |
| Avidity Partners Management LP | 1,288,948 | 0 | 0 | 0 | For |
| EcoR1 Capital, LLC | 1,272,000 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 1,257,312 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,172,512 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 1,135,541 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,108,338 | 0 | 0 | 0 | For |
| Foresite Capital Management V, LLC | 1,004,050 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 948,267 | 0 | 0 | 0 | For |
| Clearbridge Investments, LLC | 727,902 | 0 | 0 | 0 | For |
| Charles Schwab | 548,316 | 0 | 0 | 0 | For |
| Vanguard | 542,994 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 542,036 | 0 | 0 | Against |
| Ensign Peak Advisors, Inc | 456,012 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 451,352 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 355,458 | 0 | 0 | 0 | For |
| Putnam | 343,131 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 339,469 | 2,223 | 0 | 0 | For |
Institutional-manager reports, all 201 managers: 51,173,661 for, 1,139,047 against, 28 not voted, 9,388 1 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's Named Executive Officers.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Jackson National | 0 | 0 | 0 | 0 | -- |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| AllianceBernstein | 0 | 0 | 0 | 0 | -- |
| Legg Mason | 0 | 0 | 0 | 0 | -- |
| MUTUAL FUND SERIES TRUST | 0 | 0 | 0 | 0 | -- |
| First Trust | 0 | 0 | 0 | 0 | -- |
| Prudential/PGIM | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 0 | -- |
| Lord Abbett | 0 | 0 | 0 | 0 | -- |
| Putnam | 0 | 0 | 0 | 0 | -- |
| Hartford | 0 | 0 | 0 | 0 | -- |
| PENN SERIES FUNDS INC | 0 | 0 | 0 | 0 | -- |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 0 | -- |
| Goldman Sachs | 0 | 0 | 0 | 0 | -- |
| John Hancock | 0 | 0 | 0 | 0 | -- |
| MFS | 0 | 0 | 0 | 0 | -- |
| Federated Hermes | 0 | 0 | 0 | 0 | -- |
| TIAA | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 84 managers: 131,311 for, 22,684 abstained, 28,693,254 1 year, 40,858 3 year, 104 unknown. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| RTW INVESTMENTS, LP | 0 | 0 | 0 | 0 | -- |
| Wellington | 0 | 0 | 0 | 0 | -- |
| Foresite Capital Management VI LLC | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| Avidity Partners Management LP | 0 | 0 | 0 | 0 | -- |
| EcoR1 Capital, LLC | 1,272,000 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| FRANKLIN ADVISERS INC | 0 | 0 | 0 | 0 | -- |
| AllianceBernstein | 0 | 0 | 0 | 0 | -- |
| Foresite Capital Management V, LLC | 0 | 0 | 0 | 0 | -- |
| ORBIMED ADVISORS LLC | 0 | 0 | 0 | 0 | -- |
| Clearbridge Investments, LLC | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| Candriam S.C.A. | 0 | 0 | 0 | 0 | -- |
| Ensign Peak Advisors, Inc | 0 | 0 | 0 | 0 | -- |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 0 | 0 | 0 | 0 | -- |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 | 0 | 0 | 0 | -- |
| Putnam | 0 | 0 | 0 | 0 | -- |
| JENNISON ASSOCIATES LLC | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 192 managers: 1,447,203 for, 318 against, 28 not voted, 43,820,714 1 year, 481,499 3 year, 2,800 2 year. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Approved · of votes cast
Prior year: 100.0% for (June 5, 2025 meeting) unchanged
Description as filed by funds: To ratify the appointment by the Audit Committee of the Board of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
CG Oncology, Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 83,711,522 for, 4,103 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal …”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 86 asset managers below reported 28,865,680 for, 22,684 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,215,536 | 0 | 0 | 0 | For |
| T. Rowe Price | 6,951,557 | 0 | 0 | 0 | For |
| Fidelity | 2,911,157 | 0 | 0 | 0 | For |
| BlackRock | 1,829,138 | 0 | 0 | 0 | For |
| Jackson National | 785,996 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 727,381 | 0 | 0 | 0 | For |
| Charles Schwab | 541,958 | 0 | 0 | 0 | For |
| State Street | 405,333 | 0 | 0 | 0 | For |
| AllianceBernstein | 388,943 | 0 | 0 | 0 | For |
| Legg Mason | 381,329 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 366,397 | 0 | 0 | 0 | For |
| First Trust | 330,663 | 0 | 0 | 0 | For |
| Prudential/PGIM | 282,523 | 0 | 0 | 0 | For |
| Equitable | 251,573 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 245,891 | 0 | 0 | 0 | For |
| Lord Abbett | 227,058 | 0 | 0 | 0 | For |
| Putnam | 222,650 | 0 | 0 | 0 | For |
| Hartford | 205,514 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 191,487 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 176,920 | 0 | 0 | 0 | For |
| Goldman Sachs | 161,696 | 0 | 0 | 0 | For |
| John Hancock | 138,297 | 0 | 0 | 0 | For |
| MFS | 136,863 | 0 | 0 | 0 | For |
| Federated Hermes | 121,134 | 0 | 0 | 0 | For |
| TIAA | 120,636 | 0 | 0 | 0 | For |
Showing the 25 largest of 86 asset managers. All 86 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 88,007,761 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 10.47% |
| 2 | T. Rowe Price | 7.90% |
| 3 | Fidelity | 3.31% |
| 4 | BlackRock | 2.08% |
| 5 | Jackson National | 0.89% |
| 6 | FRANKLIN STRATEGIC SERIES | 0.83% |
| 7 | Charles Schwab | 0.62% |
| 8 | State Street | 0.46% |
| 9 | AllianceBernstein | 0.44% |
| 10 | Legg Mason | 0.43% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | T. Rowe Price | 11.44% |
| 2 | RTW INVESTMENTS, LP | 7.97% |
| 3 | Decheng Capital LLC | 7.24% |
| 4 | Wellington | 4.57% |
| 5 | Foresite Capital Management VI LLC | 2.52% |
| 6 | Fidelity | 2.26% |
| 7 | BlackRock | 1.61% |
| 8 | State Street | 1.49% |
| 9 | Avidity Partners Management LP | 1.46% |
| 10 | EcoR1 Capital, LLC | 1.45% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| RTW Investments, LP | 8,514,590 | 9.67% | Schedule 13G, filed August 14, 2026 |
| Vanguard Group | 6,539,482 | 7.43% | Form 13F, quarter ended March 31, 2026 |
| Decheng Capital Global Life Sciences Fund IV, L.P. | 6,371,669 | 7.24% | Proxy statement (DEF 14A), proxy filed April 24, 2026 |
| Entities affiliated with Wellington Management Group LLP | 5,512,779 | 6.26% | Proxy statement (DEF 14A), proxy filed April 24, 2026 |
| Wellington Management | 5,371,232 | 6.10% | Form 13F, quarter ended March 31, 2026 |
| BlackRock | 5,064,180 | 5.75% | Form 13F, quarter ended March 31, 2026 |
| Entities affiliated with Longitude Venture Partners | 4,662,268 | 5.30% | Proxy statement (DEF 14A), proxy filed April 24, 2026 |
| James B. Tananbaum | 4,306,174 | 4.89% | Schedule 13G, filed August 14, 2026 |
| FMR (Fidelity) | 3,764,844 | 4.28% | Form 13F, quarter ended March 31, 2026 |
| T. Rowe Price | 3,652,980 | 4.15% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 88,007,761 shares outstanding, as reported by CG Oncology, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At CG Oncology, Inc.'s shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 259 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 2,194 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's Named Executive Officers. — CG Oncology, Inc.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CG Oncology, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 8, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CG Oncology, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
CG Oncology, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “CG Oncology (CGON) 2026 Annual Meeting: Vote Results & How Funds Voted”, https://proxyvotesnow.com/company/cg-oncology-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.